GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cereno Scientific AB (FRA:4A1) » Definitions » Debt-to-Revenue

Cereno Scientific AB (FRA:4A1) Debt-to-Revenue : N/A (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cereno Scientific AB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Cereno Scientific AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.00 Mil. Cereno Scientific AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €16.55 Mil. Cereno Scientific AB's annualized Revenue for the quarter that ended in Dec. 2024 was €0.00 Mil.


Cereno Scientific AB Debt-to-Revenue Historical Data

The historical data trend for Cereno Scientific AB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cereno Scientific AB Debt-to-Revenue Chart

Cereno Scientific AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Cereno Scientific AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Cereno Scientific AB's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Cereno Scientific AB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cereno Scientific AB's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cereno Scientific AB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cereno Scientific AB's Debt-to-Revenue falls into.


;
;

Cereno Scientific AB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Cereno Scientific AB's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 16.553) / N/A
=N/A

Cereno Scientific AB's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


Cereno Scientific AB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cereno Scientific AB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cereno Scientific AB Business Description

Traded in Other Exchanges
Address
BioVentureHub, Pepparedsleden 1, Molndal, SWE, 431 83
Cereno Scientific AB is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's lead program, CS1, is a phase two dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. Cereno Scientificalso evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system.

Cereno Scientific AB Headlines

No Headlines